Taking stock of the drug industry, from the lab to the medicine chestJanuary 24, 2025Check out STAT+Sponsored By By Ed SilvermanPharmalot Columnist, Senior Writer LISELOTTE SABROE/AFP/Getty Images STAT+ | Novo Nordisk is slammed by U.K. trade group for not disclosing payments to health and patient groups Between 2015 and 2022, the preliminary report found that Novo Nordisk misreported 65 payments worth $95 million to health and patient groups. By Ed Silverman STAT+ | FDA purges material on clinical trial diversity from its site, showing stakes of Trump DEI ban Following the Trump administration's DEI ban, the FDA's move to scrub webpages has ensnared many pages focused on ensuring diversity in drug trials. By Matthew Herper and Lizzy Lawrence Chinese biotechs, a WHO departure, and post-JPM thoughts This episode, we go over our closing thoughts from the J.P. Morgan Healthcare Conference, including the chatter around Chinese drugs. By Allison DeAngelis, Elaine Chen, and Adam Feuerstein Novo Nordisk STAT+ | Novo Nordisk's next-generation obesity treatment shows promise in early study An injectable form of the drug amycretin, which is also being developed as a pill, helped patients lose a substantial amount of weight. By Andrew Joseph STAT+ | Up and down the ladder: The latest comings and goings From new hires to departures, promotions and transfers, here are the latest comings and goings in the pharmaceutical industry. By Ed Silverman More around STATCheck out more exclusive coverage with a STAT+ subscriptionRead premium in-depth biotech, pharma, policy, and life science coverage and analysis with all of our STAT+ articles.Enjoying Pharmalot? Tell us about your experienceContinue reading the latest health & science news with the STAT appDownload on the App Store or get it on Google Play STAT, 1 Exchange Place, Boston, MA©2025, All Rights Reserved.I no longer wish to receive STAT emailsUpdate Newsletter Preferences • Contact Us • Advertise with Us • View in Browser
No comments